A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(18 sites)

Japan

Kurume University Hospital, Kurume, Fukuoka

Fukushima Medical University Hospital, Fukushima, Fukushima

Mie University Hospital, Tsu, Mie-ken

Tohoku University Hospital, Sendai, Miyagi

Niigata Cancer Center Hospital, Niigata, Niigata

Saitama Medical University International Medical Center, Hidaka, Saitama

Tokushima University Hospital, Tokushima, Tokushima

The Jikei University Hospital, Tokyo, Tokyo

The Cancer Institute Hospital Of JFCR, Tokyo, Tokyo

University of Tsukuba Hospital, Tsukuba, ㅊ Ibaraki

Singapore

National University Hospital, Singapore

South Korea

Severance Hospital, Yonsei Health System, Seoul, Seoul

National Cancer Center, Goyang-si

Bundang Seoul National University Hospital, Seongnam-si

Asan Medical Center, Seoul

Korea University Guro Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University, Seoul